Medical backgrounder: Psoriasis

被引:8
作者
Travis, L
Weinberg, JM
机构
[1] St Lukes Roosevelt Hosp, Dept Dermatol, New York, NY 10025 USA
[2] Beth Israel Deaconess Med Ctr, Dept Dermatol, New York, NY 10003 USA
关键词
D O I
10.1358/dot.2002.38.12.820102
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European populations. Psoriatic lesions are extremely characteristic of the disease, which allows for simple diagnosis. A clear understanding of the pathogenesis of psoriasis does not yet exist. Hyperproliferation of keratinocytes is a further characteristic feature. Studies have depicted that the epidermal cell cycle of psoriatic lesions is shortened by approximately eight-fold more than normal. The lesions are classified as erythrosquamous, due to the erythema which develops as a result of involvement of the vasculature, and the involvement of the epidermis with scale formation. The diagnosis of psoriasis can usually be established on clinical grounds. If the clinician is in doubt, a small cutaneous punch biopsy and subsequent histopathological examination can be performed. There are multiple therapeutic options for psoriasis. First-line therapy for patients with moderate to severe psoriasis is the application of topical agents, followed by phototherapy (UVB) for more extensive disease. If extensive disease does not respond to UVB, second-line agents include psoralen plus UVA (PUVA), methotrexate, cyclosporine or other systemic agents, including novel biologic therapies. New psoriasis treatment regimens have been developed and include combination, rotational and sequential therapy. (C) 2002 Prous Science. All rights reserved.
引用
收藏
页码:847 / 865
页数:19
相关论文
共 75 条
[21]   In vitro compatibility of tazarotene with other topical treatments of psoriasis [J].
Hecker, D ;
Worsley, J ;
Yueh, G ;
Lebwohl, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (06) :1008-1011
[22]   Topical calcipotriene in combination with UVB phototherapy for psoriasis [J].
Hecker, D ;
Lebwohl, M .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1997, 36 (04) :302-303
[23]   ADDITION OF A TOPICALLY APPLIED CORTICOSTEROID TO A MODIFIED GOECKERMAN REGIMEN FOR TREATMENT OF PSORIASIS - EFFECT ON DURATION OF REMISSION [J].
HORWITZ, SN ;
JOHNSON, RA ;
SEFTON, J ;
FROST, P .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1985, 13 (05) :784-791
[24]   THE APPROACH TO PSORIASIS [J].
INGRAM, JT .
BRITISH MEDICAL JOURNAL, 1953, 2 (4836) :591-594
[25]   TACROLIMUS (FK-506) - A NEW THERAPEUTIC AGENT FOR SEVERE RECALCITRANT PSORIASIS [J].
JEGASOTHY, BV ;
ACKERMAN, CD ;
TODO, S ;
FUNG, JJ ;
ABUELMAGD, K ;
STARZL, TE .
ARCHIVES OF DERMATOLOGY, 1992, 128 (06) :781-785
[26]   Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens [J].
Jensen, P ;
Hansen, S ;
Moller, B ;
Leivestad, T ;
Pfeffer, P ;
Geiran, O ;
Fauchald, P ;
Simonsen, S .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (02) :177-186
[27]   6-THIOGUANINE THERAPY FOR PSORIASIS CAUSING TOXIC HEPATIC VENOOCCLUSIVE DISEASE [J].
KAO, NL ;
ROSENBLATE, HJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 28 (06) :1017-1018
[28]   INTERMITTENT CORTICOSTEROID MAINTENANCE TREATMENT OF PSORIASIS - A DOUBLE-BLIND MULTICENTER TRIAL OF AUGMENTED BETAMETHASONE DIPROPIONATE OINTMENT IN A PULSE DOSE TREATMENT REGIMEN [J].
KATZ, HI ;
PRAWER, SE ;
MEDANSKY, RS ;
KRUEGER, GG ;
MOONEY, JJ ;
JONES, ML ;
SAMSON, CR .
DERMATOLOGICA, 1991, 183 (04) :269-274
[29]  
Kemény L, 2001, ARCH DERMATOL, V137, P95
[30]   Duration of remission of psoriasis therapies [J].
Koo, J ;
Lebwohl, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (01) :51-59